Recombinant heparan sulfate for use in tissue engineering applications

Journal of Chemical Technology and Biotechnology

Volumn 83, Issue 4, 2008, Pages 496-504

  Whitelock, John ^a   Ma, J Leo ^a   Davies, Neil ^a   Nielsen, Natasja ^a   Chuang, Christine ^a   Rees, Martin ^b   Iozzo, Renato V ^c   Knox, Sarah ^a,d   Lord, Megan ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Growth factor; Heparan sulfate; Recombinant; Tissue engineering

Indexed keywords

BINDING SITES; CELL GROWTH; CHEMICAL ANALYSIS; FIBROBLASTS;

HEPARAN SULFATE; MITOGENS; MORPHOGENS; RECOMBINANT PROTEOGLYCAN;

TISSUE ENGINEERING;

CHONDROITIN SULFATE; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; KERATAN SULFATE; PERLECAN; PROTEOGLYCAN;

BINDING SITES; CELL GROWTH; CHEMICAL ANALYSIS; FIBROBLASTS; TISSUE ENGINEERING;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MONOLAYER CULTURE; PROTEIN BINDING; PROTEIN EXPRESSION; TISSUE ENGINEERING;

EID: 41549094095     PISSN: 02682575     EISSN: 10974660     Source Type: Journal    
DOI: 10.1002/jctb.1835     Document Type: Article

References (39)

1. Bishop JR, Schuksz M and Esko JD, Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446:1030-1037 (2007).
2. Whitelock JM and Iozzo RV, Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 105:. 2745-2764 (2005).
3. Knox SM and Whitelock JM, Perlecan: how does one molecule do so many things? Cell Mol Life Sci 63:2435-2445 (2006).
4. Winzen U, Cole GJ and Halfter W, Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters. J Biol Chem 278:30106-30114 (2003).
5. Dong S, Cole GJ and Halfter W, Expression of collagen XVIII and localization of its glycosaminoglycan attachment sites. J Biol Chem 278:1700-1707 (2003).
6. Dolan M, Horchar T, Rigatti B and Hassell JR, Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J Biol Chem 272:4316-4322 (1997).
7. Costell M, Mann K, Yamada Y and Timpl R, Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides. Eur J Biochem 243:115-121 (1997).
8. Kokenyesi R and Silbert JE, Formation of heparan sulfate or chondroitin/ dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells. Biochem Biophys Res Commun 211:262-267 (1995).
9. Friedrich MV Gohring W, Morgelin M, Brancaccio A, David G and Timpl R, Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V. J Mol Biol 294:259-270 (1999).
10. Brown JC, Sasaki T, Gohring W, Yamada Y and Timpl R, The C-terminal domain V of perlecan promotes betal integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem 250:39-46 (1997).
11. Graham LD, Whitelock JM and Underwood PA, Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains. Biochem Biophys Res Commun 256:542-548 (1999).
12. Whitelock J, Purification of perlecan from endothelial cells. Methods Mol Biol 171:27-34 (2001).
13. Whitelock JM, Murdoch AD, Iozzo RV and Underwood PA, The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271:10079-10086 (1996).
14. Lehrman AAA and Gao N, Alternative and sources of reagents and supplies of fluorophore-assisted carbohydrate electrophoresis (FACE). Glycobiology 13:1G-3G (2003).
15. Calabro A, Benavides M, Tammi M, Hascall VC and Midura RJ, Microanalysis of enzyme digests of hyaluronan and chondroitin/dermatan sulfate by fluorophore-assisted carbohydrate electrophoresis (FACE). Glycobiology 10:273-281 (2000).
16. Klock JC and Starr CM, Polyacrylamide gel electrophoresis of fluorophore-labeled carbohydrates from glycoproteins. Methods Mol Biol 76:115-129 (1998).
17. Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV and Underwood PA, Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol 18:163-178 (1999).
18. Gerena-Lopez Y, Nolan J, Wang L, Gaigalas A, Schwartz A and Fernandez-Repollet E, Quantification of EGFP expression on Molt-4 T cells using calibration standards. Cytometry A 60:21-28 (2004).
19. Harper BK, Mabon SA, Leffel SM, Halthill MD, Richards HA, Moyer KA, et al, Green fluorescent protein as a marker for expression of a second gene in transgenic plants. Nat Biotechnol 17:1125-1129 (1999).
20. Richards HA, Halfhill MD, Millwood RJ and Stewart CN Jr, Quantitative GFP fluorescence as an indicator of recombinant protein synthesis in transgenic plants. Plant Cell Rep 22:117-121 (2003).
21. Remans T, Schenk PM, Manners JM, Grof CPL and Elliott AR, A protocol for the fluorometric quantification of mGFP5-ER and sGFP(S65T) in transgenic plants. Plant Mol Biol Rep 17:385-395 (1999).
22. Kokenyesi R and Bernfield M, Core protein structure and sequence determine the site and presence of heparan sulfate and chondroitin sulfate on syndecan-1. J Biol Chem 269:12304-12309 (1994).
23. Chen RL and Lander AD, Mechanisms underlying preferential assembly of heparan sulfate on glypican-1. J Biol Chem 276:7507-7517 (2001).
24. Sugahara K and Kitagawa H, Heparin and heparan sulfate biosynthesis. IUBMB Life, 54:163-175 (2002).
25. Zhang L, David G and Esko JD, Repetitive Ser-Gly sequences enhance heparan sulfate assembly in proteoglycans. J Biol Chem 270:27127-27135 (1995).
26. Wang H, Julenius K, Hryhorenko J and Hagen FK, Systematic analysis of proteoglycan modification sites in Caenorhabditis elegans by scanning mutagenesis. J Biol Chem 282:14586-14597 (2007).
27. Smith SM, West LA, Govindraj P, Zhang X, Ornitz DM and Hassell JR, Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. Matrix Biol 26:175-184 (2007).
28. Mongiat M, Sweeney SM, San Antonio JD, Fu J and Iozzo RV, Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278:4238-4249 (2003).
29. Knox S, Merry C, Stringer S, Melrose J and Whitelock J, Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J Biol Chem 277:14657-14665 (2002).
30. Knox S, Melrose J and Whitelock J, Electrophoretic, biosensor, and bioactivity analyses of perlecans of different cellular origins. Proteomics 1:. 1534-1541 (2001).
31. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E and Leder P, Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12:240-247 (1992).
32. Springer BA, Pantoliano MW, Barbera FA, Gunyuzlu PL, Thompson LD, Herblin WF, et al, Identification and concerted function of two receptor binding surfaces on basic fibroblast growth factor required for mitogenesis. J Biol Chem 269:26879-26884 (1994).
33. Robinson CJ, Harmer NJ, Goodger SJ, Blundell TL and Gallagher JT, Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes. J Biol Chem 280:42274-42282 (2005).
34. Ibrahimi OA, Zhang F, Hrstka SC, Mohammadi M and Linhardt RJ, Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 43:4724-4730 (2004).
35. Jastrebova N, Vanwildemeersch M, Rapraeger AC, Gimenez-Gallego G, Lindahl U and Spillmann D, Heparan sulfate-related oligosaccharides in ternary complex formation with fibroblast growth factors 1 and 2 and their receptors. J Biol Chem 281:26884-26892 (2006).
36. French MM, Gomes RR Jr, Timpl R, Hook M, Czymmek K, Farach-Carson MC, et al, Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I. J Bone Miner Res 17:48-55 (2002).
37. Yang WD, Gomes RR Jr, Alicknavitch M, Farach-Carson MC and Carson DD, Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds. Tissue Eng 11:76-89 (2005).
38. Yang W, Gomes RR, Brown AJ, Burdett AR, Alicknavitch M, Farach-Carson MC, et al, Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. Tissue Eng 12:2009-2024 (2006).
39. Casper CL, Yang W, Farach-Carson MC and Rabolt JF, Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding. Biomacromolecules 8:1116-1123 (2007).